Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Hematology

What Is the Long-Term BPDCN Survivor Surveillance Schedule?

At a Glance

BPDCN survivors usually need long-term follow-up because relapse can occur in the skin, bone marrow, blood, lymph nodes, or central nervous system. Monitoring commonly includes clinic visits, CBCs, skin exams, and selected marrow or spinal-fluid tests, with frequency decreasing over time.

Because Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive cancer with a high risk of relapse—even after stem cell transplants and periods of complete remission—survivors require a rigorous, long-term clinical surveillance schedule [1][2]. While your exact timeline will be individualized by your care team, a typical long-term schedule includes frequent complete blood counts (CBC), regular full-body skin exams by an experienced dermatologist, and periodic bone marrow biopsies or lumbar punctures. The frequency of these tests decreases over time as you remain in remission. This intense lifelong monitoring is necessary to look for evidence of recurrence, because BPDCN can return in the skin, bone marrow, blood, lymph nodes, or central nervous system (CNS) [3].

Routine Clinic Visits and Blood Tests

Your regular oncology visits will include a physical examination, where your doctor will check your lymph nodes and spleen, and order lab work.

  • Complete Blood Counts (CBC): Frequent CBCs are a cornerstone of your follow-up care. A CBC measures the different types of cells in your blood, including red cells, white cells, and platelets. Sudden drops in healthy cell counts or the appearance of abnormal cells can sometimes be an early warning sign of a bone marrow relapse [3].
  • Limitations of Blood Tests: It is important to know that a normal CBC does not guarantee the cancer hasn’t returned in isolated areas like the skin or CNS. Additionally, abnormal blood counts do not always mean a relapse; they can be caused by medications, infections, or graft-versus-host disease (GVHD) after a transplant.

Full-Body Skin Exams

BPDCN very commonly involves the skin, and relapses can appear as new skin nodules, bumps, or discolorations months or years after treatment [4][5].

  • Dermatology Visits: Regular full-body skin exams by an experienced dermatologist are a typical part of the surveillance schedule. Your hematology team will coordinate how often these are needed based on your original skin involvement.
  • What You Can Do: Check your own skin between visits. However, keep in mind that many post-treatment changes or bruises are benign. Report new or changing spots to your care team so they can be properly assessed, rather than trying to diagnose them yourself.

Periodic Bone Marrow Biopsies

The bone marrow—the spongy tissue inside your bones where blood cells are made—is a common site for BPDCN to recur [4].

  • Checking for MRD: Your schedule will likely include periodic bone marrow biopsies. These tests look for measurable residual disease (MRD), which refers to cancer cells present at levels too low to be seen with a standard microscope. Using highly sensitive laboratory techniques like multiparameter flow cytometry, doctors can detect microscopic traces of BPDCN [6].
  • Frequency: Serial biopsies are not usually done indefinitely. They are typically scheduled at specific post-treatment milestones or if your blood counts drop. While a negative MRD result is highly encouraging, it does not completely eliminate the risk of relapse.

Central Nervous System (CNS) Monitoring

BPDCN can infiltrate the central nervous system (CNS), which includes the brain and spinal cord, sometimes without causing any neurological symptoms [7]. Because of this risk, CNS assessment is considered a critical part of BPDCN management [8].

  • Lumbar Punctures: A lumbar puncture (often called a spinal tap) is a procedure used to sample the cerebrospinal fluid (CSF) that surrounds your brain and spinal cord. Periodic lumbar punctures may be scheduled during your first year or post-transplant period, particularly if you are receiving preventative CNS therapies. Your doctor will always check your platelet counts first to ensure the procedure is safe.
  • Symptom-Driven Testing: Later in your survivorship, lumbar punctures are usually only performed if there is a clinical concern or if you develop concerning symptoms [9][10].

When to Seek Immediate Medical Attention

Between your scheduled visits, you must know who to call and when to seek emergency care.

  • Emergency Symptoms: Sudden severe headaches, sudden vision changes, sudden weakness, confusion, or difficulty walking require immediate emergency medical evaluation. These can be signs of CNS involvement or other serious complications [9][10]. Do not wait for your next clinic appointment.
  • Urgent Clinic Calls: Call your transplant or oncology clinic’s 24-hour line for fevers (ask your team for your specific temperature threshold), unusual bleeding, rapidly spreading rashes, or other signs of infection.

Common questions in this guide

How often are BPDCN survivors monitored after treatment?
The schedule depends on your treatment, transplant history, skin involvement, blood counts, and time in remission. Visits and testing are usually more frequent early after treatment and become less frequent when remission continues, but long-term follow-up remains important because BPDCN can return.
What does a CBC show during BPDCN follow-up?
A complete blood count, or CBC, measures red blood cells, white blood cells, and platelets. Falling counts or abnormal cells can be an early sign of relapse in the bone marrow, but a normal CBC cannot rule out relapse in the skin or central nervous system, and abnormal results can also have other causes.
Why are skin exams part of BPDCN surveillance?
BPDCN often involves the skin, and a relapse may appear as a new nodule, bump, or area of discoloration. An experienced dermatologist can perform a full-body examination, while you can report new or changing spots between visits without trying to diagnose them yourself.
Will I need bone marrow biopsies or lumbar punctures forever?
Not necessarily. Bone marrow biopsies are usually performed at selected milestones or when blood counts or other findings raise concern, and they may check for measurable residual disease using sensitive testing. Lumbar punctures may be used during the first year or after a transplant, especially with preventive central nervous system treatment, and later are often reserved for symptoms or other clinical concerns.
What is MRD testing in BPDCN follow-up?
Measurable residual disease, or MRD, means looking for very small numbers of cancer cells that cannot be seen with a standard microscope. Testing such as multiparameter flow cytometry can find these cells in a bone marrow sample. A negative result is encouraging but does not remove the possibility of future relapse.
Which symptoms mean I need urgent or emergency care?
Go to the emergency department for a sudden severe headache, sudden vision change, weakness, confusion, or difficulty walking. Call your oncology or transplant team's 24-hour line for fever, unusual bleeding, a rapidly spreading rash, or possible infection, using the temperature threshold your team gave you. Do not wait for the next scheduled visit.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific treatment and transplant history, what will my surveillance schedule look like for the first year, and how will the frequency of visits decrease over time?
  2. 2.Which tests (like bone marrow biopsies or lumbar punctures) are scheduled routinely for me, and which will only be done if there is a clinical concern?
  3. 3.How often should I see a dermatologist for full-body skin exams, and who will coordinate those visits?
  4. 4.What specific emergency symptoms or temperature threshold should prompt me to go to the ER versus calling the clinic's after-hours line?
  5. 5.Will we be monitoring for measurable residual disease (MRD) using flow cytometry in my scheduled bone marrow biopsies?

References

References (10)
  1. 1

    Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel.

    Pagano L, Zinzani PL, Pileri S, et al.

    HemaSphere 2023; (7(3)):e841 doi:10.1097/HS9.0000000000000841.

    PMID: 36844178
  2. 2

    Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.

    Wang S, Wang X, Liu M, Bai O

    Annals of hematology 2018; (97(4)):563-572 doi:10.1007/s00277-018-3259-z.

    PMID: 29455234
  3. 3

    An Unusual Manifestation of Blastic Plasmacytoid Dendritic Cell Neoplasm as a Testicular Tumor.

    Pak DM, Tretiakova MS

    Case reports in pathology 2019; (2019()):9196167 doi:10.1155/2019/9196167.

    PMID: 31687245
  4. 4

    Successful treatment with biweekly CHOP for bone marrow relapse of blastic plasmacytoid dendritic cell neoplasm.

    Ono K, Ise M, Ikebe D, et al.

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2017; (58(2)):150-154 doi:10.11406/rinketsu.58.150.

    PMID: 28321093
  5. 5

    Case Report of Anti-CD123 Chimeric Antigen Receptor T-Cell Therapy Followed by Radiotherapy for a Recurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem Cell Transplantation.

    Jiang YL, Li Q, Yuan T, et al.

    OncoTargets and therapy 2020; (13()):3425-3430 doi:10.2147/OTT.S250016.

    PMID: 32368098
  6. 6

    Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.

    Wang W, Khoury JD, Miranda RN, et al.

    Haematologica 2021; (106(4)):1047-1055 doi:10.3324/haematol.2020.247569.

    PMID: 32241840
  7. 7

    Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.

    Martín-Martín L, Almeida J, Pomares H, et al.

    Oncotarget 2016; (7(9)):10174-81 doi:10.18632/oncotarget.7101.

    PMID: 26840087
  8. 8

    Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management.

    Shimony S, Luskin MR, Gangat N, et al.

    American journal of hematology 2025; (100(8)):1408-1422 doi:10.1002/ajh.27737.

    PMID: 40525728
  9. 9

    Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: A case report.

    Gao NA, Wang XX, Sun JR, et al.

    Experimental and therapeutic medicine 2015; (9(4)):1109-1112 doi:10.3892/etm.2015.2236.

    PMID: 25780395
  10. 10

    Blastic Plasmacytoid Dendritic Cell Neoplasm without Cutaneous Manifestation: A Case Report.

    Razzeto A, Garala P, Amoozgar B, et al.

    The American journal of case reports 2021; (22()):e932887 doi:10.12659/AJCR.932887.

    PMID: 34550964

This page describes common BPDCN follow-up practices for informational purposes only and does not constitute medical advice. Your hematology, oncology, dermatology, and transplant teams should set your personal surveillance schedule and interpret your results.